Moteur de recherche d’entreprises européennes
UK funding (374 014 £) : Co-conception et évaluation de « chaussettes intelligentes » instrumentées par capteurs (MPATIX) pour améliorer la gestion de la détresse et de l’agitation chez les personnes … Ukri 01/08/2023 UK Research and Innovation, Royaume Uni
Vue d’ensemble
Texte
Co-conception et évaluation de « chaussettes intelligentes » instrumentées par capteurs (MPATIX) pour améliorer la gestion de la détresse et de l’agitation chez les personnes atteintes de démence
| Abstract | More than 70% of the 430,000 care home residents in the UK have dementia or similar memory problems (Alzheimer's Society/ONS). By 2035 the UK dementia population will double to 1.6m. Dementia care is challenging and expensive, costing £35b in the UK. As communication becomes more difficult, people can struggle to request help when they are in distress. This leads to challenging behavioural symptoms (aggression, anxiety) often reflecting resolvable care issues such as discomfort/lack of pain management. Currently, around half of people with dementia experience behavioural symptoms linked to unmanaged distress. Critically, carers face challenges successfully meeting the needs of people with dementia who cannot identify or communicate why/that they are in distress. There is an unmet need for technological solutions which support carers to promptly respond to individuals' unique needs and situational triggers. Milbotix have developed MPATIX Smart Socks, which incorporate sensors that track pulse, sweat, temperature and motion to give accurate insights on the wearer's wellbeing. Utilising our novel machine learning algorithm and mobile application, we can provide unique anxiety/distress information, without disruption for people with dementia or their carers. Looking and feeling like normal socks, the MPATIX socks are machine washable and don't require charging. MPATIX integrates with care home data systems allowing the system to augment existing workflows for easier adoption. Funded by Alzheimer's Society, the UK's leading dementia charity, Milbotix has developed a validated TRL 6 prototype, which has demonstrated reliability at detecting anxiety (74%-98% accurate). This project will develop a trial-ready version, enabling the necessary large-scale RCT which fully quantifies and demonstrates the care provider and individual benefits of deployment. With MPATIX, we are ideally positioned to address a rapidly growing market opportunity and emerging social challenge in an ageing population. |
| Category | Collaborative R&D |
| Reference | 10055596 |
| Status | Closed |
| Funded period start | 01/08/2023 |
| Funded period end | 30/04/2025 |
| Funded value | £374 014,00 |
| Source | https://gtr.ukri.org/projects?ref=10055596 |
Participating Organisations
| MILBOTIX LTD |
£280 576,00 |
| BRUNEL UNIVERSITY LONDON |
£78 810,00 |
| SOUTHERN HEALTHCARE (WESSEX) LTD | |
| UNIVERSITY OF EXETER |
£14 627,00 |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Milbotix Ltd., Chipping Norton, Royaume Uni.